NanoViricides is trading 12.31% higher at $1.46 after announcing positive juvenile-mouse safety results for NV-387 on October 20, 2026. - The candidate was well tolerated at the highest tested dose. - No mortality or treatment-related adverse findings were reported, supporting potential pediatric clinical trials.